TRC 253
Alternative Names: JNJ 63576253; TRC-253Latest Information Update: 24 Mar 2025
At a glance
- Originator Janssen Pharmaceutica
- Developer Janssen Pharmaceutica; TRACON Pharmaceuticals
- Class Antineoplastics; Aza compounds; Ethers; Fluorinated hydrocarbons; Nitriles; Organic sulfur compounds; Picolines; Piperidines; Pyridines; Small molecules; Spiro compounds
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 12 Nov 2024 Discontinued - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (TRACON Pharmaceuticals website, March 2025)
- 22 Mar 2021 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (TRACON Pharmaceuticals pipeline, March 2021)
- 30 Sep 2020 TRC 253 is still in phase I/II trial for Prostate cancer in USA (NCT02987829)